FDA approves Takeda drug Orzeyful for narcolepsy type 1
The US Food and Drug Administration approved Takeda's drug Orzeyful for the treatment of narcolepsy type 1. This is a national approval for a rare disease. The drug is an orexin receptor agonist.
Why it matters
The approval provides a new treatment option for people with narcolepsy type 1.
CHECKED · 1 SOURCE · UNCORROBORATED
← All news